{
    "clinical_study": {
        "@rank": "41785", 
        "arm_group": [
            {
                "arm_group_label": "HL040XC(Atorvastatin+Losartan)", 
                "arm_group_type": "Experimental", 
                "description": "HL040XC lag time released combination drug"
            }, 
            {
                "arm_group_label": "Losartan + Atorvastatin", 
                "arm_group_type": "Active Comparator", 
                "description": "Coadministration group"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is:\n\n      To evaluate the pharmacokinetics and safety of an experimental combination tablet containing\n      20 mg atorvastatin and 50 mg losartan potassium when administered orally as a single dose to\n      healthy male subjects, compared with the concomitant administration of 20 mg atorvastatin\n      and 50 mg losartan potassium tablets."
        }, 
        "brief_title": "A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hypertension", 
            "Hyperlipidemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperlipidemias", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male subjects between 19 and 50 years of age, inclusive.\n\n          2. Subjects who weigh at least 121 pounds (55 kg), and are within \u00b1 20% of their of\n             ideal body weight (IBW). IBW (kg) = [height (cm) - 100] x 0.9.\n\n          3. Subjects who don't have any congenital or chronic disease.\n\n          4. Subjects who don't have any clinically significant abnormality on vital sign\n             measurement, physical examination, clinical lab test, and ECG test at Screening.\n\n          5. Subjects who are able to read and understand the consent form.\n\n        Exclusion Criteria:\n\n          1. Subjects who have any history or presence of hypersensitivity to HMG-CoA reductase\n             inhibitors such as atorvastatin or angiotensin receptor blockers such as losartan.\n\n          2. Subjects who have any medical history that may affect the absorption, distribution,\n             metabolism, and excretion of study drugs (e.g., cardiovascular, respiratory, renal,\n             endocrinal, hematological, digestive, neurological, or psychiatric disease).\n\n          3. Subjects who have a creatinine clearance < 80 mL/min, which is calculated by\n             Cockcroft-Gault equation: (140 - age) x (Wt in kg) / (72 x sCr).\n\n          4. Subjects who had a severe injury or surgery within 4 weeks prior to Screening.\n\n          5. Subjects who have a positive drug screen.\n\n          6. Subjects who take any prescription or herbal drug within 1 week prior to Screening.\n\n          7. Subjects who take any over-the counter (OTC) drug, which may affect this study or the\n             subject's safety according to the judgment of investigator, at Screening.\n\n          8. Subjects who take any herbal drug containing St. John's Wort or other drugs, which\n             are metabolized by CYP3A4 enzyme or inhibit or stimulate CYP enzyme (e.g.,\n             itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease\n             inhibitor, nefazodone) within 4 weeks prior to Screening.\n\n          9. Subjects who have abnormal meal pattern that may affect the absorption, distribution,\n             metabolism, and excretion of study drugs (e.g., taking grapefruit juice over 1 L per\n             day).\n\n         10. Subjects who received an investigational product within 4 weeks prior to Screening.\n\n         11. Subjects who have donated blood within 6 weeks prior to Screening.\n\n         12. Subjects who consume alcohol over 21 units per week (1 unit = 150 mL of wine, 360 mL\n             of beer, or 45 mL of 40% alcohol) and can't accept the prohibition of alcohol during\n             this clinical study.\n\n         13. Subjects who smoke more than 10 cigarettes per day.\n\n         14. Subjects who have low blood pressure (systolic \u2264 100 mmHg or diastolic \u2264 65 mmHg) or\n             high blood pressure (systolic \u2265 150 mmHg or diastolic \u2265 95 mmHg) at Screening.\n\n         15. Subjects who test positive on serology HBsAg, HCV Ab, HIV Ab or VDRL at Screening.\n\n         16. Subjects who have active liver disease or elevated serum transaminase level higher\n             than 3 times of upper limit of normal.\n\n         17. Subjects who have the inability in the opinion of the investigator to comply with the\n             protocol."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01806324", 
            "org_study_id": "HL-040XC-US-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "HL040XC(Atorvastatin+Losartan)", 
                "description": "single dose", 
                "intervention_name": "HL040XC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Losartan + Atorvastatin", 
                "description": "Single dose", 
                "intervention_name": "Losartan + Atorvastatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Atorvastatin", 
                "Losartan"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21201"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate its bioequivalency in Cmax and AUC of each test group", 
                "measure": "Cmax", 
                "safety_issue": "Yes", 
                "time_frame": "0 ~ 48hr"
            }, 
            {
                "description": "To evaluate bioequvalency of each group", 
                "measure": "AUC", 
                "time_frame": "0~48HR"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01806324"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "HanAll BioPharma Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "HanAll BioPharma Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}